Eli Lilly to discontinue four unprofitable insulin drugs

Eli Lilly will remove four insulin drugs with low or falling sales from the U.S. market, including its remaining animal-based insulins. Biosynthetic insulins began replacing animal insulins in 1983. Two percent of the 3.5 million insulin users in the U.S. depend on these products and will have until the end of the year to find replacements. The discontinued products make up a small percentage of the company's total insulin sales of more than $2 billion a year.

View Full Article in:

Indianapolis Star (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL